K2 Principal Fund, L.P. I Teos Therapeutics, Inc. Call Options Transaction History
K2 Principal Fund, L.P.
- $210 Million
- Q3 2024
Call Options
3 transactions
Others Institutions Holding ITOS
# of Institutions
166Shares Held
36.6MCall Options Held
1.95MPut Options Held
374K-
Black Rock Inc. New York, NY3.73MShares$27.1 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.18MShares$23.1 Million0.45% of portfolio
-
Boxer Capital, LLC San Diego, CA2.95MShares$21.4 Million1.6% of portfolio
-
Mpm Asset Management LLC Cambridge, MA2.74MShares$19.9 Million19.24% of portfolio
-
Tang Capital Management LLC San Diego, CA2.41MShares$17.5 Million2.09% of portfolio
About iTeos Therapeutics, Inc.
- Ticker ITOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,575,300
- Market Cap $258M
- Description
- Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...